ABSTRACT: Azaspiracids (AZA) are polyether marine dinoflagellate toxins that accumulate in shellfish and represent an emerging human health risk. Although human exposure is primarily manifested by severe and protracted diarrhea, this toxin class has been shown to be highly cytotoxic, a teratogen to developing fish, and a possible carcinogen in mice. Until now, AZA's molecular target has not yet been determined. Using three independent methods (voltage clamp, channel binding assay, and thallium flux assay), we have for the first time demonstrated that AZA1, AZA2, and AZA3 each bind to and block the hERG (human ethera-go-go related gene) potassium channel heterologously expressed in HEK-293 mammalian cells. Inhibition of K + current for each AZA analogue was concentration-dependent (IC 50 value range: 0.64−0.84 μM). The mechanism of hERG channel inhibition by AZA1 was investigated further in Xenopus oocytes where it was shown to be an open-state-dependent blocker and, using mutant channels, to interact with F656 but not with Y652 within the S6 transmembrane domain that forms the channel's central pore. AZA1, AZA2, and AZA3 were each shown to inhibit [ 3 H]dofetilide binding to the hERG channel and thallium ion flux through the channel (IC 50 value range: 2.1−6.6 μM). AZA1 did not block the K + current of the closely related EAG1 channel. Collectively, these data suggest that the AZAs physically block the K + conductance pathway of hERG1 channels by occluding the cytoplasmic mouth of the open pore. Although the concentrations necessary to block hERG channels are relatively high, AZAinduced blockage may prove to contribute to the toxicological properties of the AZAs.
■ INTRODUCTION
Azaspiracids (AZAs) are polyether toxins produced by toxigenic species of Azadinium 1,2 that can accumulate in shellfish and cause human illness. 3 Although there have been no deaths associated with the AZA toxins, humans exposed to AZAs experience severe gastrointestinal illness. 4, 5 Over the past decade, extensive progress has been made on elucidating the chemical structure of AZA and its various analogues. To date, over 20 naturally occurring analogues of AZA have been described, 6, 7 but thus far only AZA1, AZA2, and AZA3 ( Figure  1 ) appear to present a human health risk and are subject to food safety regulations. 8 In vivo studies in mice exposed to AZA1 revealed severe effects such as deformation of intestinal epithelial villi 9, 10 as well as damage to T and B lymphocytes, accumulation of fatty acid deposits in the liver, increased prevalence of lung tumors, and hyperplasia within the stomach lining. 11, 12 In vitro studies have shown the AZAs to be highly cytotoxic causing a variety of cytoskeletal effects 13−18 and stimulation of cAMP production and cytosolic calcium release. 19, 20 In spinal cord neurons, AZA1 was shown to inhibit bioelectrical activity through a mechanism that was independent of voltage-gated sodium (Na + ) or calcium (Ca 2+ ) current. 21 Recent findings suggest the AZAs cause apoptosis, 13, 22, 23 although this toxin class may have multiple molecular targets 13, 14 and also concurrently induce necrotic pathways. To date, the mechanism(s) of action of the AZA toxin class has not been identified, but during a series of preliminary activity screening assays wherein AZA1 was tested toward various protein phosphatases, kinases, G-protein coupled receptors, and ion channels, there was an indication that AZA1 had an adverse effect on a member of the ether-a-go-go (EAG) K + channel family. EAG K + channels were first discovered in Drosophila where the eag mutant was associated with spontaneous repetitive axon firing in motor neurons. 24 It was later determined that eag encodes a K + channel subunit 25 that functions to conduct a delayed rectifier K + current. 26 A human homologue (hEAG) of Drosophila eag and a related gene (hERG, human ether-a-go-go related gene) were later discovered in a human hippocampus cDNA library. 27 hERG K + channels are transcriptionally expressed in a broad array of cell/ tissue types including heart (differentially expressed across the 4 chambers), brain, liver, kidney, breast, pancreas, and colon with the highest levels of expression in heart and brain tissue. 28 Expression is cell cycle dependent, involved in apoptosis, 29 and commonly up-regulated in cancerous cells. 30 The hERG (also known as KCNH2) encodes the pore forming α subunit of the voltage-gated potassium channel Kv11.1. 27 The channel consists of four α subunits, each with six transmembrane domains (S1−S6) where S5 and S6 form the channel's central pore. In the heart, hERG proteins coassemble to form the channel that conducts the rapid delayed rectifier K + current (I Kr ), which is critical for the repolarization phase of the cardiac action potential. 31 Mutations in this channel have been associated with congenital long (and short) QT syndromes, characterized by prolonged (and shortened) ventricular repolarization and increased risk of fatal cardiac arrhythmia. The hERG channel has been shown to be the target for class III antiarrhythmic drugs such as dofetilide, which can reduce the risk of re-entrant arrhythmias by prolonging the action potential duration and refractory period without slowing conduction velocity in the myocardium. However, block of this channel by class III agents and numerous noncardiac drugs with poor predictability based on structure can also cause excessive prolongation of QT intervals and induce arrhythmia (acquired long QT syndrome). Because of the wide spectrum of compounds that can block hERG channels and induce arrhythmia, drug regulatory agencies have issued recommendations for the evaluation of hERG activity in the early preclinical stages of drug development.
A variety of natural toxins are known to target hERG channels, 32 including but not limited to scorpion venoms, 33 spider venoms, 34 sea anemone toxins, 35 and the algal toxins ciguatoxin, 36 and gambierol. 37 The aim of the current study was to examine the effects of AZAs on human ERG channels, providing the first mechanistic description of this interaction.
■ MATERIALS AND METHODS
Toxin Isolation. The AZAs were isolated from cooked mussel tissue (M. edulis) collected in 2005 from Bruckless, Donegal, Ireland. The toxins were purified using a 7-step protocol as outlined by Kilcoyne et al. 38 and stored at −20°C in methanol. Purity (>95%) was confirmed by LC-MS/MS and NMR spectroscopy. For experimental use, the AZAs were dried under N 2 gas and resuspended in DMSO.
Mammalian Cell Voltage Clamp Protocols and Data Analysis. HEK-293 cells stably transfected with hERG cDNA (GenScript Inc., Piscataway, NJ, USA) were regularly subcultured in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum and 200 μg/mL G418 antibiotic (cat. #G8168, SigmaAldrich, St. Louis, MO, USA). HEK-293 cells expressing hERG were plated in 35 mm dishes at least 24 h prior to the day of experiment and maintained at 37°C/5% CO 2 . The extracellular solution for whole cell patch clamp recordings was composed of (in mM): 137 NaCl; 1.2 MgCl 2 ; 5.4 KCl; 10 glucose; 10 HEPES; and 2 CaCl 2 . pH was adjusted to 7.4 with NaOH. The osmolarity was adjusted to 305 mOsm with sucrose. The intracellular solution for whole cell patch clamp recordings was composed of (in mM): 140 KCl; 1 MgCl 2 ; 5 EGTA; 10 HEPES; and 5 Na 2 ATP. The pH was adjusted to 7.2 with KOH. The osmolarity was adjusted to 295 mOsm with sucrose.
For electrophysiology recordings, micropipets were pulled from borosilicate glass that had a tip resistance of 3−5 MΩ when filled with intracellular solution. For each experiment, a single dish of cells was removed from the incubator, washed twice with room temperature (RT) extracellular solution, and then placed on the microscope stage. A commercial patch clamp amplifier was used for the whole cell recordings. The tail currents were evoked at RT once every 30 s by a 3 s −50 mV repolarizing pulse following a 2 s +50 mV depolarizing test pulse. The holding potential was −80 mV and a 50 ms pulse to −50 mV preceded each test pulse and served as a baseline for calculating the amplitude of the peak tail current. Only stable cells with recording parameters above threshold were subjected to AZA exposure. The hERG channel currents were allowed to stabilize over a 3 min period in the presence of vehicle alone prior to AZA addition. The cells were kept in the test solution until the peak tail current was stable (<5% change) for ∼5 sweeps or for a maximum of 6 min, whichever came first. Criteria for acceptance of measurements were as follows: (i) whole-cell membrane resistance (Rm) was greater than 1,000 MΩ throughout the experiment, (ii) initial tail current was greater than 300 pA, (iii) series resistance value following the establishment of wholecell mode was less than 12 MΩ, and (iv) the leak current that the cell began with or that developed over time was less than 10% of the ionic current magnitude (up to a maximum of 80 pA). The hERG channel antagonist terfenadine (cat. #T9652, Sigma-Aldrich, St. Louis, MO, USA) was used as a positive control. All test agent stock solutions were resuspended in DMSO and diluted in extracellular solution. DMSO additions never exceeded 0.3% vol/vol, which itself did not affect hERG currents (data not shown).
Voltage clamp data were recorded by Clampex (version 10.1) and data acquisition and analyses were performed using pCLAMP (version 10.1; Molecular Devices, CA, USA) and Origin 8 (OriginLab Corp., MA, USA). Peak tail amplitudes were plotted as a function of the sweep number. Five peak tail current measurements at the steady state AZA addition were averaged and used as the control current amplitude. Four or five peak tail current measurements at the steady state after AZA addition were averaged and used as the remaining current amplitude after inhibition by AZA. The % inhibition of the hERG channel due to AZA was calculated from the following equation: % inhibition = (1 − (remaining current amplitude)/(control 42, 43 using a GeneClamp 500 amplifier and a Digidata 1322A data acquisition system controlled by pCLAMP 8.2 software (Molecular Devices, Inc., Sunnyvale, CA, USA). Oocytes were placed in a static, small volume (75 μL) recording chamber. The bathing solution contained (in mM) 98 NaCl, 2 KCl, 1 CaCl 2 , 1 MgCl 2 , and 5 HEPES; pH 7.6. Agarose-cushion microelectrodes were fabricated as described 44 and had tip resistances of 0.4−0.6 MΩ when backfilled with 3 M KCl.
During an initial equilibration period, oocytes were voltage clamped to a holding potential of −80 mV, and 1-s pulses to a test potential (V t ) of 0 mV were applied every 10 s until current magnitude reached a steady-state level. The current−voltage (I−V t ) relationships for hERG1 or hEAG1 channels were determined by applying 2-s pulses to test potentials ranging from −70 to +40 mV in 10 mV increments. The holding potential was −80 mV, and tail currents were elicited at −70 mV. Conductance−voltage (G−V t ) relationships for hERG1 were determined by tail current analysis. Peak outward tail currents were normalized to their maximum value (at +40 mV) and plotted as a function of test potential. The resulting plot was fitted to a Boltzmann function (eq 1):
where V 0.5 is the half-point of activation, and k is the slope factor. The G−V relationship for hEAG1 channels was determined by analysis of test pulse currents. The outward current at the end of 2-s pulses (I peak ) was divided by the electrical driving force, test voltage minus reversal potential (V t − E rev ). The resulting relationship was fitted to a Boltzmann function and extrapolated to more positive potentials to estimate the maximum current (I max ) under control conditions. The G/G max for each oocyte was then estimated as I peak /I max . The timedependent decay of hERG1 tail currents elicited at −70 mV after activation pulses to +40 to 0 mV were fitted to a biexponential function (Levenberg−Marquardt method) to determine the time constants for channel deactivation. After obtaining baseline recordings, a small aliquot of AZA1 stock solution (500 μM in 10% DMSO) was added directly to the bathing solution to obtain the final desired toxin concentration. During the onset of AZA1 action, 1 s pulses to a V t of 0 mV were applied every 10 s until a new steady-state current level was achieved. The I−V t relationship protocol was then repeated in the presence of AZA1.
Off-line data analysis was performed with Clampfit 8.2 (Molecular Devices, CA, USA), Origin 8.5 (OriginLab, MA, USA), and Excel (Microsoft Corp., WA, USA) software. Data are expressed as the mean ± SEM (n = number of oocytes).
hERG Channel Binding Assay. The hERG channel binding assay was performed as described by Huang et al. 45 Briefly, membranes were prepared from hERG-expressing HEK-293 cells, and competition assays were performed in 96-well plates using [
3 H]dofetilide (1.5 nM) in hERG binding buffer (hBB) containing (in mM) 135 NaCl, 5 KCl, 0.8 MgCl 2 , 10 HEPES, 10 glucose, 1 EGTA, and 0.01% BSA, pH 7.4. The AZA test compounds were diluted in hBB from 500 μM stock solutions in 10% DMSO/PBS (pH 7.4). Radioactivity retained on glass fiber filters was counted on a Perkin-Elmer 1450 Microbeta Trilux plate counter, and data are presented as disintegrations per minute (dpm). Dofetilide was used as a positive control. All data are presented as means ± SEM of three replicate wells. IC 50 and 95% confidence interval determinations were calculated using four parameter, nonlinear regression analysis (GraphPad Prism, ver. 5.0c, CA, USA). Data (dpm per well) were also analyzed by nonlinear regression, one-site saturation binding (GraphPad Prism) to obtain K i values for each AZA analogue according to the Cheng−Prusoff equation. 46 An experimentally determined K d value of 4.7 nM was used for [ 3 H]dofetilide. 45 Thallium Flux Assay. The thallium (Tl + ) flux assay was performed using the FluxOR Potassium Ion Channel Assay kit (cat. #F10016; Invitrogen, CA, USA) with modifications as outlined by Huang et al. 45 Briefly, hERG-expressing HEK-293 cells described above, were plated in 384-well plates, loaded with Tl + -sensitive FluxOR reagent, and incubated with AZA for 15 min prior to Tl + flux across hERG channels via stimulation with a K + /Tl + -containing solution. Fluorescence intensity at 490/525 nm (ex./em.) of each well was simultaneously monitored using the FLIPR Tetra (MDS Analytical Technologies, Sunnyvale, CA, USA) with ScreenWorks 2.9 software. Terfenadine was used as a positive control. Data are expressed as Tl + flux as determined from the initial slope of the curve following hERG channel stimulation. All data are presented as means ± SEM of three replicate wells. IC 50 and 95% confidence interval determinations were calculated using four parameter, nonlinear regression analysis (GraphPad Prism, ver. 5.0c, CA, USA).
■ RESULTS AZA1, AZA2, and AZA3 Block hERG Channel Current in Transfected Mammalian Cells. Voltage clamped HEK-293 cells stably expressing hERG channels were exposed to various concentrations of AZA1, AZA2, and AZA3 (0.064−1.9 μM), and hERG currents were monitored while voltage was adjusted. Representative traces and replicated experimental data illustrate that hERG currents were inhibited by AZA1 in a concentration-dependent manner with a maximum inhibition of 79.5 ± 1.8% (mean ± SEM, n = 3) elicited by 1.9 μM AZA1 ( Figure 2) . As determined by patch clamp experiments, the AZA1 IC 50 value was 0.84 μM (Table 1) . Similarly, AZA2 and AZA3 caused nearly identical concentration-dependent inhibition of hERG currents ( Figure 2B ; representative traces not shown). Maximal inhibition by AZA2 and AZA3 (1.9 μM) was 87.3 ± 0.95% and 79.7 ± 1.6% with IC 50 hERG channels, elicited concentration-dependent inhibition of hERG currents (data not shown) with an IC 50 of 0.019 μM (Table 1) .
AZA1 Blocks hERG1 Channels Heterologously Expressed in Oocytes. The mechanisms of AZA1 induced inhibition of hERG1 channels were studied in greater detail using Xenopus laevis oocytes. WT hERG1 channel currents measured in oocytes were slightly less sensitive to AZA1 than currents in HEK-293 cells but had inhibitory effects similar to those determined by binding studies in these cells described below. At a saturating concentration (10 μM), AZA1 reduced the peak outward hERG1 current measured at −10 mV in oocytes to 19.0 ± 2.4% of the control (n = 6). The onset of hERG1 channel block in oocytes by 10 μM AZA1 developed exponentially with a time constant of 1.5 min ( Figure 3A and B). The effect of 10 μM AZA1 on the peak outward hERG1 currents (I peak ) elicited during pulses to a range of test voltages was determined. Steady-state changes in current magnitude were observed after 5−8 min. Representative currents are shown in Figure 3C (control) and D (5 min AZA1), and I−V t relationships are plotted in Figure 3E . I peak was reduced at all potentials. AZA1 did not alter the voltage dependence of rectification ( Figure 3C , open triangles), indicating that it had no effect on the voltage dependence of hERG channel inactivation. The voltage dependence of channel activation was determined by plotting the normalized peak tail currents measured at −70 mV as a function of V t ( Figure 3F ). AZA1 reduced I tail at all voltages and inhibited peak I tail by 75 ± 2% (n = 6) but did not significantly alter the V 0.5 or slope factor of the G−V t curve determined using 2-s activating pulses. AZA1 caused a modest acceleration in the rate of current deactivation. At −70 mV, tail currents decayed with a biexponential time course with time constants of 249 ± 8 ms and 1003 ± 57 ms under control conditions and 205 ± 17 ms and 745 ± 44 ms in the presence of AZA1 (n = 6). The relative amplitude of the slow component of deactivation was slightly reduced by AZA1 from 0.80 ± 0.02 to 0.72 ± 0.02.
Channel State Dependent Block by AZA1. To determine if AZA1 inhibition of hERG1 current depends on the state of the channel, we compared the time-course of currents recorded during single test pulses applied in the absence of AZA1 and again after a prolonged pulse-free period of AZA1 exposure. Control current was first activated with a very long (37.8 s) pulse to 0 mV (Figure 4 ). AZA1 (10 μM) was then added to the recording chamber, and the oocyte was held at −70 mV without pulsing to keep channels in a closed state for 4 min. At the end of the 4 min incubation, a second long pulse to 0 mV was applied. Current traces for the two test pulses are superimposed in Figure 4A for the complete pulse, and in Figure 4B for the initial 1.35 s of the pulse. AZA1 had a minimal effect on current during the initial 0.5 s of the pulse; afterward, inhibition developed gradually during the long pulse and neared completion by the end of the pulse. To more clearly illustrate the time-dependent development of block by AZA1, the current trace recorded in the presence of AZA1 was divided by the control current trace and the resulting ratio (I AZA1 / I control ) plotted as a function of time in Figure 4C . The ratio I AZA1 /I control was initially 1.0 (indicating no closed state block), decayed with a biexponential time course, and the extrapolated steady state ratio was 0.19. Thus, the amount of current was reduced to 19% of control during a single long pulse to 0 mV, similar to the average inhibition observed after 5−8 min of continual pulsing ( Figure 4E ). These findings suggest that AZA1 preferentially blocks the open state of hERG1 channels. Mutation of F656 in S6 Segment of hERG1 Attenuates Block by AZA1. Almost all compounds that block the open state of hERG1 channels appear to interact with a few residues in the S6 segment whose side chains face toward the central cavity. 41, 47 Two of the most commonly recognized molecular determinants of hERG1 channel block are Phe656 and Tyr652 in S6; mutations in these residues have been shown to attenuate block by many drugs.
39−41 Therefore, we determined if mutation of either one of these residues affected block by AZA1. F656T hERG1 channels were insensitive to 10 μM AZA1 at test potentials negative to −20 mV ( Figure 5A and B) . At test potentials greater than −20 mV, currents were slightly inhibited (e.g., peak I tail reduced by 7 ± 1%; n = 5). Y652A hERG1 channel currents were inhibited by 10 μM AZA1 at all test potentials ( Figure 5C ) with 76 ± 3% (n = 5) block of peak I tail ( Figure 5D ), similar to the block observed for WT hERG1 channels. AZA1 had no effect on the voltage dependence of F656T hERG1 channel activation ( Figure 5B ) but shifted the V 0.5 for activation of Y652A hERG1 channels by −5 mV ( Figure 5D ). Together, the findings of reduced sensitivity of F656T hERG1 channels to block by AZA1 and the timedependent inhibition of current following a pulse-free incubation with AZA1 (Figure 4) indicate that AZA1 is an open channel blocker.
AZA1 Is a Weak Blocker of Human EAG1 Channels. To determine the channel specificity of AZA1, we examined the effect of 10 μM AZA1 on hEAG1 channels heterologously expressed in oocytes. AZA1 slightly reduced hEAG1 currents at all test potentials examined ( Figure 6A−C) . At a test potential of +40 mV, AZA1 blocked hEAG1 current by 15 ± 0.8% (n = Figure 6D ). Thus, AZA1 is a more potent blocker of hERG1 than hEAG1 K + channels.
AZA1, AZA2, and AZA3 Bind to hERG Channels. Membrane preparations from HEK-293 cells stably expressing hERG channels were used for binding assays. Various concentrations of AZA1, AZA2, and AZA3 (0.001 to 10 μM) were tested, and each AZA analogue was found to inhibit the binding of radiolabeled dofetilide, a known hERG inhibitor, in a concentration-dependent manner (Figure 7) . The amount of bound [ 3 H]dofetilide is expressed as disintegrations per minute (dpm) (mean ± SEM) per well. Relative to vehicle controls, hERG binding by AZA1, AZA2, and AZA3 (10 μM) was reduced to 19.7 ± 1.4% (n = 2), 22.3 ± 1.0% (n = 3), and 29.3 ± 1.6% (n = 3) with IC 50 values of 2.1 μM, 2.6 μM, and 6.6 μM, respectively (Table 1) . Similarly, K i values (with 95% confidence intervals) were 2.9 (1.3−6.6) μM, 3.6 (1.9−6.9) μM, and 8.3 (3.5−20) μM, respectively. As such, there were no statistical differences in the potencies of the three analogues (AZA1 = AZA2 = AZA3). Dofetilide, a well-known inhibitor of hERG channels, elicited concentration-dependent inhibition of hERG binding (data not shown) with an IC 50 of 8.8 nM (Table  1) .
AZA1, AZA2, and AZA3 Inhibit Thallium Flux through the hERG Channel. The flux of thallium (Tl + ) through hERG channels was monitored in the presence and absence of AZA1, AZA2, and AZA3 (0.001 to 30 μM). Each analogue of AZA inhibited the flux of thallium in a concentration-dependent manner ( Figure 8 ). All data (mean ± SEM, n = 3) are expressed as the Tl + flux as determined from the initial slope of the curve following the addition of stimulation solution. Relative to vehicle controls, thallium flux via the hERG was reduced by AZA1, AZA2, and AZA3 (30 μM) to 10.7 ± 0.56%, 9.6 ± 0.79%, and 16.6 ± 0.50% with IC 50 values of 4.2 μM, 5.1 μM, and 6.2 μM, respectively (Table 1 ). As such, there were no significant potency differences between the AZA analogues (AZA1 = AZA2 = AZA3). Terfenadine elicited a concentrationdependent inhibition of Tl + flux (data not shown) with an IC 50 of 8.4 μM ( Table 1) .
■ DISCUSSION
Azaspiracids are potent algal toxins that have resulted in multiple human intoxication events in Europe and the United States.
4,5 Because of the growing food safety concerns related to Table 1 . this human health threat, many investigators have focused on elucidation of the molecular target(s) for this toxin class. However, despite these efforts, no specific target has been identified. For the first time, we present conclusive evidence that the AZA toxins are a new class of hERG K + channel inhibitors.
Chemical Research in Toxicology
A wide range of drugs (and toxins) have been shown to inhibit hERG1 currents, and in-depth studies indicate that most of these compounds block K + conductance by binding to a canonical site and plugging the central cavity that is formed by the four S6 segments of the homotetrameric channel. 48 The side chains of two aromatic residues (Y652 and F656) located in each of the four S6 segments of hERG1 face toward the central cavity and are commonly involved with hydrophobic and/or π-stacking interactions with drugs that bind to the central cavity. [39] [40] [41] 47, 49 Similar to AZA1 (C 47 H 71 NO 12 ), the macrolide antibiotic erythromycin (C 37 H 67 NO 13 ) also blocks hERG1 rapidly in an open-state-dependent manner, and analysis of mutant channels and molecular modeling indicate that it interacts with phenylalanine reside at position 656 but not with tyrosine reside at position 652. 50 AZA1 and erythromycin have molecular weights of 842 and 733, respectively, and are much larger than the vast majority of drugs known to block hERG1 channels. Although Y652 is located only a single helical turn above F656 on S6, it is positioned further into the central cavity and may be beyond reach of compounds as large as AZA1 and erythromycin. Thus, while both AZA1 and erythromycin are open-state-dependent blockers of hERG1, it seems their large size precludes their access into the deep interior of the central cavity. We propose that AZA1 physically blocks the K + conductance pathway of hERG1 channels by occluding the cytoplasmic mouth of the open pore. Pore block at this site might also explain why AZA1 does not appreciably alter the kinetics or voltage dependence of hERG1 channel gating. Collectively, these findings are consistent with our previous patch-clamp study using spinal cord neuronal networks wherein we concluded that AZA1 inhibited bioelectrical activity through a mechanism that was independent of voltage-gated sodium (Na + ) or calcium (Ca 2+ ) currents. 21 However, it should be noted that bioelectrical activity was inhibited by low nanomolar concentrations of AZA1, whereas in the present study, much higher concentrations were necessary (i.e., micromolar).
EAG1 channels are closely related to ERG1 channels and yet are much less sensitive to block by AZA1. This difference in potency has been noted for most well studied hERG1 blockers and has been attributed at least in part to the orientation of the two aromatic residues in the S6 segment of the two channels. 51 Perhaps Phe468 in hEAG1 (equivalent to Phe656 in hERG1) is not positioned for optimum hydrophobic interaction with AZA1 when the channels are in the open state.
Relative to AZA1, AZA2 is methylated at the C8 position (8-methyl-azaspiracid), whereas AZA3 is demethylated at the C22 position (22-demethyl-azaspiracid) (Figure 1) . Despite the methylation differences of these three AZA analogues, there does not appear to be much difference in relative potencies toward hERG K + channel inhibition. Each AZA analogue was capable of inhibiting hERG K + channel current in transfected HEK-293 cells with IC 50 values ranging between 0.64 and 0.84 μM. AZA2 was slightly more potent, but the potencies of AZA3 and AZA1 were not different. However, this same trend in relative potency was not observed via hERG channel binding (K i values between 2.9 and 8.3 μM) and thallium flux where all AZA analogues were found to be of the same relative potency. In contrast, it has been shown that there are very distinctive structure−activity relationships with respect to the cytotoxic potencies of these same AZA analogues at much smaller concentrations (i.e., low nanomolar). AZA2 and AZA3 have been shown to be 8.3-and 4.5-fold more potent than AZA1, respectively.
14 These potency trends have also been corroborated in vivo via mouse lethality, 52, 53 which have formed the basis for calculating the toxic equivalence factors (TEFs) currently used by the European Union for food safety regulation (1.8 for AZA2 and 1.4 for AZA3). 8 AZAs are known to be highly potent cytotoxic agents to all cell types tested 15, 54 and have been shown to induce apoptosis. 22 Similarly, many hERG channel inhibitors are also known inducers of apoptosis 29 and can cause cytotoxicity toward a wide variety of cell lines. 55, 56 Although cardiomyocytes and neurons are most sensitive, the broad distribution of hERG channels across many cell/tissue types likely plays a role in mediating this cytotoxic response. When administered via intraperitoneal injection to rodents, AZAs can cause a variety of neurotoxic, immunotoxic, and hepatotoxic effects that can result in death. 52, 53, 57 In fact, the very first AZA studies used contaminated shellfish extracts that were injected into mice and caused a neurotoxin-like response followed by death. 58, 59 This response quite feasibly could have been via potassium channel inhibition.
In vitro, AZAs have been shown to directly enter into cells. 60 When administered orally, AZAs are systemically distributed 9, 10 and can cause severe gastrointestinal degradation followed by a variety of other effects including hepatotoxicity and immunotoxicity. 11, 12 Many of the other open channel blockers of hERG (i.e., methanesulfonanilides such as E-4031, MK-499, and dofetilide) can have a wide spectrum of toxicological effects in vivo but generally do not have a history of gastrointestinal side effects 61, 62 despite the presence of hERG channels in intestinal epithelial cells. In vivo exposure to mechanistically similar hERG channel blocking compounds such as erythromycin can have profound hepatotoxic effects 63 not unlike those induced by AZAs but commonly have their most dramatic effects on the heart, causing prolongation of cardiac action potentials, 64 which may lead to a potentially lethal form of cardiac arrhythmia Figure 8 . AZAs inhibit thallium flux through hERG potassium channels. Various concentrations of AZA1, AZA2, and AZA3 were tested using the thallium (Tl + ) flux assay. All data (mean ± SEM; n = 3) were analyzed using nonlinear sigmoidal dose−response. Terfenadine was used as a positive control. Calculated IC 50 values are shown in Table 1 . called torsades-de-pointes. During a recent mini-pig feeding study, animals were acutely administered AZA-contaminated feed (200 μg AZA total /kg) and monitored over a 24 h period. Despite an absence of overt symptoms, there were histological indications of gastrointestinal perturbations, and coincident with peak AZA total blood concentrations (ca. 3.2 nM at 4 h), peripheral lymphocyte differential gene expression using DNA microarrays were suggestive of a strong inflammatory response including markers of cardiomyopathy (unpublished data). These preliminary findings provide the first physiological linkage between potassium channel inhibition and AZA toxicity. As such, future in vivo studies testing AZAs should assess potential cardiotoxic effects of these toxins (i.e., electrocardiogram, molecular markers, etc.).
A mechanism of action for the AZA toxin class has been sought for many years by multiple investigators. Although we have confirmed that AZAs are low affinity hERG potassium channel inhibitors, it is almost certain that the AZAs have other molecular targets as discussed previously. 13, 14, 19 There are discrepancies between the concentrations and relative potencies of the AZA analogues necessary to cause cytotoxicity (sub-to low-nanomolar with AZA2 > AZA3 > AZA1), and those that are needed to inhibit hERG channel current (≥640 nM with AZA2 > AZA1 = AZA3). Similarly, in vivo toxic doses tend to be much lower for AZAs (≤500 μg/kg) 9,10,52,53 relative to many of the other known hERG channel inhibitors (>5 mg/ kg). Finally, our previous study has shown that AZA1 is highly cytotoxic to wild-type HEK-293 cells (EC 50 values range between 2.5 and 4.6 nM) 15 that do not have hERG K + channels. As such, these discrepancies suggest that another molecular target(s) may be responsible for the cytotoxic effects of the AZAs. The effects of long-term exposure of AZAs to human health are unknown. AZA1 has been shown to be a possible carcinogen in rodents 11 and a teratogen to developing fish where we specifically noted dose-dependent bradycardia, 65 which has been demonstrated for several other hERG blockers 66 including erythromycin. 67 It is conceivable that humans consuming AZAs via contaminated shellfish may be at risk for teratogenicity and/or torsades-de-pointes; however, targeted diagnostic evaluation of teratogenicity and cardiac function will be required to confirm such a response.
■ CONCLUSIONS
For the first time, we have conclusively identified the hERG channel as a molecular target for the AZA toxins. Through the use of voltage clamp, channel binding studies, and ion flux assays, we have demonstrated that AZA1, AZA2, and AZA3 bind to and block potassium current through hERG channels. AZA1 was shown to be an open-state-dependent blocker of hERG1 that interacts with F656 within the S6 transmembrane domain that forms the channel's central pore. We propose that AZA1 physically blocks the K + conductance pathway of hERG1 channels by occluding the cytoplasmic mouth of the open pore. Although AZAs block with low affinity, these findings set the stage for future studies assessing the involvement of hERG channel blocking in AZA induced toxicity. Furthermore, these findings may facilitate the identification of other molecular targets and the development of a functional channel binding bioassay that will be useful for rapid, high-throughput screening assays of naturally contaminated seafood. 
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